mild® MOTION Study Enrollment

Michigan Interventional Pain Center has recently concluded its candidate enrollment in the mild® MOTION Study.
 
Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), has concluded their enrollment into its nationwide, multi-center study of its mild® procedure. The novel, prospective, randomized controlled study uses clinically validated, patient-reported outcome measures to identify improvements in pain and function, and captures objective measures of participants’ activity levels using Fitbit activity trackers.   
 
The mild procedure is a clinically proven outpatient LSS treatment that removes the cause of stenosis through a portal the size of a baby aspirin. It requires no implants, no general anesthesia, no stitches, and no overnight hospital stay."  

The MOTION Study has enrolled patients 50-80 years of age to provide important data to help physicians and patients make early treatment decisions for LSS sufferers. The first MOTION Study patient was enrolled at Michigan Interventional Pain Center in Brownstown, Michigan by Razmig Haladjian, MD, an interventional pain specialist. The last MOTION Study patient was enrolled by Dr. Haladjian in December of 2019. 
 
"A major step forward in interventional pain occurred with the first patient enrolled in the MOTION Study, a level 1, prospective, randomized, multi-center study that evaluates subjective and objective functional measures," said Dr. Tim Deer, an interventional pain specialist, president and CEO of The Spine and Nerve Center of the Virginias and national principal investigator for the MOTION Study. "This important, activity-based study will generate evidence that further supports minimally invasive LSS treatments to improve patients' quality of life and reduce the use of opioids," added Dr. Deer.
 
The mild procedure has been performed on more than 20,000 patients and its safety and efficacy have been analyzed in more than 13 clinical studies and 20 publications. Study data has shown clinically meaningful and statistically significant mobility improvement and pain reduction, with no serious device- or procedure-related complications in any clinical trial.
 
"We are proud to continue to add meaningful data to our extensive body of evidence on the mild procedure," said Eric Wichems, president and CEO of Vertos Medical. "The MOTION Study will provide powerful real-world, quality-of-life data that will help patients and health care providers make informed decisions on the mild procedure as an early treatment choice."
 
For more information about Vertos Medical, or the MOTION Study, please visit www.vertosmed.com.